Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Celldex Ends Barzolvolimab Development In Atopic Dermatitis After Phase 2 Trial Misses Key Endpoints

(RTTNews) - Celldex Therapeutics, Inc. (CLDX) on Thursday stated it is discontinuing development of barzolvolimab in atopic dermatitis (AD) after the Phase 2 trial missed its primary and secondary endpoints.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Friday 20 November →